Genmab says head and neck cancer drug cuts death risk by 50% with Merck’s Keytruda

Genmab (GMAB) stock surges as head and neck cancer cuts death risk by 50%, with Merck’s (MRK) Keytruda sending Bicara Therapeutics (BCAX) lower. Read more here.

CryptoAlerta — análise de criptomoedas e mercado em tempo real